Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT02037945 · ClinicalTrials.gov registry record · NA
18F-Fluorocholine (18F-FCho) to Distinguish Necrosis From Recurrence in Brain Metastases
A NA study, sponsored by Memorial Sloan Kettering Cancer Center.
- Completed
- Registry status
- NA
- Development phase
- 19
- Enrollment target
NCT02037945: Completed NA study, sponsored by Memorial Sloan Kettering Cancer Center.
NCT02037945 is a NA study that has completed, run by Memorial Sloan Kettering Cancer Center. The registered enrollment target is 19 participants. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT02037945, a NA study, has completed, sponsored by Memorial Sloan Kettering Cancer Center.
- COMPLETED
- Registry status
- NA
- Development phase
- 19 participants
- Enrollment target
Study Summary
The main purpose of this study is to determine the distribution of 18F Fluorocholine (18F-FCH) in the brain which can help distinguishing radiation-induced scarring from tumor regrowth. In addition, the study will measure levels of 18F-FCH in the blood and (if applicable) in the brain lesion tissue that is removed as part of the planned brain surgery.
Interventions
- PROCEDURE 18F-FCH PET Scan
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 19 participants |
| Start Date | 2014-01 |
| Est. Completion | 2022-12-08 |
| Phase | NA |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT02037945
The ClinicalTrials.gov registry entry for NCT02037945 describes a study currently listed as completed, categorized as NA. The registered enrollment target is 19 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Memorial Sloan Kettering Cancer Center, which has 1,884 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 1 intervention - of which 18F-FCH PET Scan is the first listed.
NCT02037945 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT02037945 about?
NCT02037945 is a clinical study titled "18F-Fluorocholine (18F-FCho) to Distinguish Necrosis From Recurrence in Brain Metastases". The main purpose of this study is to determine the distribution of 18F Fluorocholine (18F-FCH) in the brain which can help distinguishing radiation-induced scarring from tumor regrowth. In addition, the study will measure levels of 18F-FCH in the blood and (if applicable) in the brain lesion tissue ...
What is the current status of trial NCT02037945?
This trial is currently completed. It is a NA study. The enrollment target is 19 participants. The study started on 2014-01. Estimated completion is 2022-12-08.
What interventions are being tested in trial NCT02037945?
The interventions under investigation include: 18F-FCH PET Scan (PROCEDURE).
Who is sponsoring clinical trial NCT02037945?
This trial is sponsored by Memorial Sloan Kettering Cancer Center, which has 1,884 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, the data changelog, or report a data error.